about
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionFunctions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targetingHigh interstitial fluid pressure - an obstacle in cancer therapyExpression of GADS enhances FLT3-induced mitogenic signaling.Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.Novel nano-sized MR contrast agent mediates strong tumor contrast enhancement in an oncogene-driven breast cancer modelEffect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancerPericytes contribute to airway remodeling in a mouse model of chronic allergic asthmaIncreasing tumor uptake of anticancer drugs with imatinib.Wnt5a Signals through DVL1 to Repress Ribosomal DNA Transcription by RNA Polymerase I.Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DDDeficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic disseminationDistinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transitionFibroblasts as architects of cancer pathogenesisBone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.Hallmarks of cancer: interactions with the tumor stroma.Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Functional subsets of mesenchymal cell types in the tumor microenvironment.Protein detection using proximity-dependent DNA ligation assays.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancerVascular endothelial growth factor B controls endothelial fatty acid uptake.Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer.Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.Of mice and men: a comparative study of cancer-associated fibroblasts in mammary carcinoma.Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapyEditorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment.A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.Consensus guidelines for the use and interpretation of angiogenesis assaysSpatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencingRibosome biogenesis during cell cycle arrest fuels EMT in development and diseaseTherapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma
P50
Q24595357-08A28581-6E45-4945-99AB-A6EEF0BCCF2DQ28755868-6D8D50B8-C3E8-4B23-888A-E0CC13ACDB71Q29619719-545AF6D8-0EC7-4B9E-AE34-CC07FE0537C8Q30009017-03C4EA52-A758-4E1B-BA6D-4B9428542F03Q33806670-4D8E8256-C5EC-4754-AB4C-D324E75B41D4Q34306808-8B5F6584-B28D-45DC-8F16-4BB28D0596F8Q34343317-18D37D9F-BBF0-4229-A8FC-71FCACB82A62Q35068030-A03230B3-5498-46E0-8A0A-551319020A59Q35275345-67AE1EB9-F997-4EAD-8397-43FF4AAA244CQ35791268-97C59E97-DB57-476A-B38C-F0708D41EE23Q36097475-31521ED0-6414-44D5-880B-F8831A9A4A23Q36607541-0BD4D5A5-C022-4790-8847-465C650B1700Q36694132-E2A91C1D-8212-4333-83F7-3A7355CB0925Q36903863-16DC887B-8D8F-4059-A99F-49FB7A060165Q37162704-BCCEA92E-D6F4-4636-A3E4-B87FCE0CC740Q37178453-BCE5BBBF-5924-437E-BD7A-BDA44B2CD6F0Q37340780-AA484DB3-E464-4C33-AC7D-E7A015769227Q37704659-C2D3DA60-8EE6-423D-9480-70C4582A1FE1Q37718307-F53F7923-6645-4471-A2B7-2281EED0BFEBQ38174516-D562B66E-A64E-47A8-997F-AE694D5FB64DQ38177504-F20D8CCA-AF95-4B1E-8776-22828D175389Q38289736-B7852F4B-106E-401B-A433-ABA131FD9FFCQ38381981-CA295C12-3C5B-4044-BF85-C96943C3B97CQ38830951-5657F586-E233-4B61-BD23-5DFC864FAE46Q38863811-0D82A1BF-6C19-48A6-8447-F5A99335651FQ39542406-1332194B-C55A-457C-B0DB-C1740F450D83Q39727853-2995C2C1-9B22-423C-8D40-B68DBF83C39EQ39753483-E8D76126-5AA6-4A12-B714-EF516FC7D76BQ40513874-3CE0E7A8-8A50-401D-8802-028895BE0C81Q41900072-9E40FC6F-0B0E-4711-8B68-7FE26567ACFFQ42140314-23A2C75F-4FB3-4BAD-BAF8-07DE2275FE79Q42620772-5F87B500-6BF2-416C-86AC-E85F6B5D1C5FQ42783558-EC1DB9BF-747D-4FFE-A9AB-0C2EC2BD04D8Q45158856-924D0904-50D8-4322-B137-CC4555D59E76Q48144964-E333E50C-02B9-4FE3-B439-67D2624087FCQ52660791-A76523F6-C922-4CB2-B41C-F73F3A0A2162Q56374651-2EC5354D-679E-4F4D-9455-8024BB065AF7Q59794209-18FAE445-3891-48C0-B48D-0CFF2D7579F8Q64062488-4A0E291A-B2CD-4EE1-A402-677F7700D089Q64130568-63AEFA30-4D78-4A65-B1CF-D6C2344511B6
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Kristian Pietras
@ast
Kristian Pietras
@en
Kristian Pietras
@es
Kristian Pietras
@nl
type
label
Kristian Pietras
@ast
Kristian Pietras
@en
Kristian Pietras
@es
Kristian Pietras
@nl
prefLabel
Kristian Pietras
@ast
Kristian Pietras
@en
Kristian Pietras
@es
Kristian Pietras
@nl
P108
P1960
xraZigYAAAAJ
P21
P31
P496
0000-0001-6738-4705
P569
1974-01-01T00:00:00Z